New hope for rare pancreatic cancer: experimental drug enters trial
NCT ID NCT07121478
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called lurbinectedin in people with high-grade pancreatic neuroendocrine tumors (a rare, fast-growing cancer) who have already tried standard treatments. The goal is to see if the drug can shrink tumors or stop them from growing. About 46 adults will take part in this Phase 2 trial.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE TUMOR OF PANCREAS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Cancer Center
Goyang-si, Gyeonggi-do, 10408, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New risk score aims to predict which pancreatic tumors will return after surgery
- Promising drug trial for rare pancreatic cancer stopped early
- Could chemo after surgery stop pancreatic tumor return?
- New pill shows promise against tough cancers in early trial
- Massive pancreas tissue bank launches to unlock disease secrets
- FITBIT FOR CANCER: STUDY TESTS IF STEP COUNTS PREDICT SURVIVAL